⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of ClinSync Clinical Research Pvt. Ltd. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
ClinSync Clinical Research Pvt. Ltd.
↗Hyderabad, India
ClinSync Clinical Research is a specialized Contract Research Organization (CRO) established in 2011, headquartered in Hyderabad, India. The company provides end-to-end clinical development services, including Phase I-IV clinical trials, bioequivalence and bioavailability (BA/BE) studies, pharmacovigilance, and clinical data management for the pharmaceutical, biotech, biosimilar, and medical device industries.
ClinSync operates a state-of-the-art facility in Hyderabad with a 160-bed clinical pharmacology unit and has established a strong regulatory track record with agencies including the USFDA and CDSCO. The company is noted for its expertise in special population studies and has expanded its operations internationally.
CLASSIFICATION
Company Type:CRO
Therapeutic Areas:
Industry:CRO
Sub-Industry:Clinical Trials and Bioequivalence Studies
SIZE & FINANCIALS
Employees:51-200
Revenue:$1M-$5M
Founded:2011
Ownership:private
Status:operating
PIPELINE
Modalities:Small molecule, Biosimilars
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
COMPETITION
Position:Niche Player
Competitors:IQVIA, Parexel, Syneos Health, Fortrea, Medpace, Sai Life Sciences
LEADERSHIP
Key Executives:
Satya Suresh Venkata Attili - Director
Koteswara Prasad Sripathipanditaradhyula - Director
Board Members:Satya Suresh Venkata Attili, Koteswara Prasad Sripathipanditaradhyula, Sandhya Nandiraju, Rambabu Maddela
LINKS
Website:clinsynccro.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with ClinSync Clinical Research Pvt. Ltd.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.